Related Experiment Videos
Current and future directions in medical therapy: hypercalcemia
1Clinic of Endocrinology/Bone Diseases and Supportive Care Clinic, Institute J. Bordet, University Libre de Bruxelles, Brussels, Belgium.
Cancer
|July 18, 2000
Summary
Bisphosphonates are the standard treatment for tumor-induced hypercalcemia (TIH), effectively normalizing serum calcium in over 90% of cancer patients. Newer agents offer improved efficacy and simpler administration for managing this condition.
Area of Science:
- Oncology
- Pharmacology
- Bone Metabolism
Background:
- Tumor-induced hypercalcemia (TIH) results from increased osteoclast activity and bone resorption.
- Inhibited bone formation and enhanced kidney calcium reabsorption contribute to elevated serum calcium levels in cancer patients.
Purpose of the Study:
- To review clinical trials on hypercalcemia treatment in cancer patients.
- To emphasize recent advancements in bisphosphonate therapy for TIH.
Main Methods:
- Review of recent clinical trials in hypercalcemic cancer patients.
- Emphasis on bisphosphonate efficacy and administration routes.
Main Results:
- Rehydration and bisphosphonates are standard TIH treatment.
- Clodronate (1500 mg infusion) achieves normocalcemia in ~80%; pamidronate (90 mg) in >90%.
- Potent bisphosphonates like ibandronate and zoledronate show promise for improved results and simplified treatment schemes.
Conclusions:
- Bisphosphonates are the established standard for cancer hypercalcemia, with >90% success rates.
- Ongoing research explores new antiosteoclastic compounds, including osteoprotegerin, for potential faster and more effective TIH treatment.